S&P 500   3,958.90 (+0.03%)
DOW   33,795.00 (-0.17%)
QQQ   280.90 (+0.12%)
AAPL   141.52 (+0.25%)
MSFT   241.05 (+0.30%)
META   109.87 (+0.37%)
GOOGL   94.93 (-0.27%)
AMZN   92.61 (+0.21%)
TSLA   182.40 (+0.87%)
NVDA   156.47 (+0.05%)
NIO   11.30 (+7.62%)
BABA   82.66 (+3.51%)
AMD   73.29 (-0.14%)
T   19.04 (+0.16%)
MU   53.69 (-2.59%)
F   13.76 (+0.07%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.46 (+0.40%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   281.07 (+0.04%)
S&P 500   3,958.90 (+0.03%)
DOW   33,795.00 (-0.17%)
QQQ   280.90 (+0.12%)
AAPL   141.52 (+0.25%)
MSFT   241.05 (+0.30%)
META   109.87 (+0.37%)
GOOGL   94.93 (-0.27%)
AMZN   92.61 (+0.21%)
TSLA   182.40 (+0.87%)
NVDA   156.47 (+0.05%)
NIO   11.30 (+7.62%)
BABA   82.66 (+3.51%)
AMD   73.29 (-0.14%)
T   19.04 (+0.16%)
MU   53.69 (-2.59%)
F   13.76 (+0.07%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.46 (+0.40%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   281.07 (+0.04%)
S&P 500   3,958.90 (+0.03%)
DOW   33,795.00 (-0.17%)
QQQ   280.90 (+0.12%)
AAPL   141.52 (+0.25%)
MSFT   241.05 (+0.30%)
META   109.87 (+0.37%)
GOOGL   94.93 (-0.27%)
AMZN   92.61 (+0.21%)
TSLA   182.40 (+0.87%)
NVDA   156.47 (+0.05%)
NIO   11.30 (+7.62%)
BABA   82.66 (+3.51%)
AMD   73.29 (-0.14%)
T   19.04 (+0.16%)
MU   53.69 (-2.59%)
F   13.76 (+0.07%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.46 (+0.40%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   281.07 (+0.04%)
S&P 500   3,958.90 (+0.03%)
DOW   33,795.00 (-0.17%)
QQQ   280.90 (+0.12%)
AAPL   141.52 (+0.25%)
MSFT   241.05 (+0.30%)
META   109.87 (+0.37%)
GOOGL   94.93 (-0.27%)
AMZN   92.61 (+0.21%)
TSLA   182.40 (+0.87%)
NVDA   156.47 (+0.05%)
NIO   11.30 (+7.62%)
BABA   82.66 (+3.51%)
AMD   73.29 (-0.14%)
T   19.04 (+0.16%)
MU   53.69 (-2.59%)
F   13.76 (+0.07%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.46 (+0.40%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   281.07 (+0.04%)
NASDAQ:ALLO

Allogene Therapeutics - ALLO Stock Forecast, Price & News

$9.31
-0.95 (-9.26%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.11
$10.65
50-Day Range
$8.76
$11.53
52-Week Range
$6.43
$19.25
Volume
4.50 million shs
Average Volume
1.68 million shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.70

Allogene Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
176.0% Upside
$25.70 Price Target
Short Interest
Bearish
39.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of Allogene Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.38) to ($2.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

819th out of 1,043 stocks

Biological Products, Except Diagnostic Industry

138th out of 172 stocks

ALLO stock logo

About Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Stock News Headlines

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 5.4%
The Lithium "Lie"
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China controls more than 90% of this vital ingredient. But the U.S. just classified graphite as "essential for America's National Defense"... and one little-known company is looking to win big in the energy war with China.
JMP Securities Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)
JMP Securities Reaffirms Their Buy Rating on BioAtla (BCAB)
The Lithium "Lie"
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China controls more than 90% of this vital ingredient. But the U.S. just classified graphite as "essential for America's National Defense"... and one little-known company is looking to win big in the energy war with China.
Allogene Therapeutics
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Company Calendar

Last Earnings
11/02/2022
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
308
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.70
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+176.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-257,010,000.00
Net Margins
-126,580.16%
Pretax Margin
-126,580.18%

Debt

Sales & Book Value

Annual Sales
$38.49 million
Book Value
$5.13 per share

Miscellaneous

Free Float
101,235,000
Market Cap
$1.34 billion
Optionable
Not Optionable
Beta
0.59

Key Executives

  • Dr. Arie S. Belldegrun F.A.C.S. (Age 73)
    FACS, M.D., Co-Founder & Exec. Chairman
    Comp: $726.91k
  • Dr. David D. Chang M.D. (Age 62)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $1.09M
  • Mr. Joshua A. Kazam (Age 45)
    Co-Founder & Director
    Comp: $657.16k
  • Dr. Eric Thomas Schmidt Ph.D. (Age 52)
    Chief Financial Officer
    Comp: $655.5k
  • Dr. Alison Moore Ph.D. (Age 55)
    Chief Technical Officer
    Comp: $743.55k
  • Mr. Veer BhavnagriMr. Veer Bhavnagri (Age 39)
    Gen. Counsel & Compliance Officer
    Comp: $653.37k
  • Dr. Rafael G. Amado M.D. (Age 58)
    Exec. VP of R&D
    Comp: $910.72k
  • Ms. Barbra Sasu
    Chief Scientific Officer
  • Mr. Stephen Cheng
    Chief Information Officer
  • Ms. Christine Cassiano
    Chief Communications Officer













ALLO Stock - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price forecast for 2023?

9 Wall Street analysts have issued 12 month price targets for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $11.00 to $35.00. On average, they expect the company's stock price to reach $25.70 in the next year. This suggests a possible upside of 176.0% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How have ALLO shares performed in 2022?

Allogene Therapeutics' stock was trading at $14.92 at the beginning of 2022. Since then, ALLO stock has decreased by 37.6% and is now trading at $9.31.
View the best growth stocks for 2022 here
.

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our ALLO earnings forecast
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) released its earnings results on Wednesday, November, 2nd. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.04. Allogene Therapeutics had a negative trailing twelve-month return on equity of 37.74% and a negative net margin of 126,580.16%. During the same quarter in the previous year, the company earned ($0.57) earnings per share.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.69%), Vanguard Group Inc. (4.97%), State Street Corp (4.63%), Price T Rowe Associates Inc. MD (4.10%), Primecap Management Co. CA (3.39%) and Dimensional Fund Advisors LP (1.20%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $9.31.

How much money does Allogene Therapeutics make?

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $1.34 billion and generates $38.49 million in revenue each year. The company earns $-257,010,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

The company employs 308 workers across the globe.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.

This page (NASDAQ:ALLO) was last updated on 11/30/2022 by MarketBeat.com Staff